Ion Asset Management’s Protalix BioTherapeutics PLX Stock Holding History

Ion Asset Management’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-157,171	Closed	-$2.14M	–	15
2017 Q1	$2.14M	Sell	157,171 -246,330	-61%	-$2.21M	0.75%	12
2016 Q4	$1.8M	Buy	+403,501	New	+$1.8M	0.76%	13

Other funds holding PLX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Ion Asset Management's PLX Position: Q2 2017 in Review

Ion Asset Management sold out of Protalix BioTherapeutics (PLX) in Q2 2017, closing a stake of 157,171 shares — an estimated $2.14M sold.

Ion Asset Management first reported a position in PLX in Q4 2016 and held it in 2 quarters. The position peaked at $2.14M in Q1 2017. 34 funds tracked by Wall St. Rank hold PLX as of Q2 2017.

Ion Asset Management reported no remaining Protalix BioTherapeutics position as of Q2 2017 after selling out during the quarter.
Ion Asset Management sold 157,171 Protalix BioTherapeutics shares in Q2 2017, an estimated $2.14M.
Ion Asset Management first reported a position in Protalix BioTherapeutics in Q4 2016 and held it in 2 quarters.
Ion Asset Management's Protalix BioTherapeutics position peaked at $2.14M in Q1 2017.
34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2017.

Based on Ion Asset Management's 13F filing for Q2 2017, filed 14 Aug 2017.